Sleep Apnea
Also known as: Sleep-disordered breathing, Resting, Sleep, Inactive, Quiet
Methodology & AI Transparency ⓘ
Sleep Apnea Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Sleep apnea is a common disorder that causes your breathing to stop or get very shallow.
- 2 Real-world patient consensus: Mapped to Insomnia, Sleep Apnea & Sleep Health under ICD-10-CM G47.30 for Sleep Apnea clinical workups.
- 3 Typical cash cost range: Workup highlights for Sleep Apnea (G47.30): CBT-I behavioral sleep in Sleep Apnea (G47.30: efficiency tracking).
- 4 Top reported side effects / signs: Follow-up benchmark in Sleep Apnea: maintaining Nocturnal Oxygen Saturation in Sleep Apnea (G47.30: (SpO2)) within >= 94% nadir > 90% (G47.30).
Ask our AI Specialists anything about Sleep Apnea
What Is Sleep Apnea?
Sleep apnea is a common disorder that causes your breathing to stop or get very shallow. Breathing pauses can last from a few seconds to minutes. They may occur 30 times or more an hour. The most common type is obstructive sleep apnea. It causes your airway to collapse or become blocked during sleep. Normal breathing starts again with a snort or choking sound. People with sleep apnea often snore loudly. However, not everyone who snores has sleep apnea. You are more at risk for sleep apnea if you are overweight, male, or have a family history or small airways. Children with enlarged tonsils or adenoids may also get it.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Sleep Apnea (code G47.30) is or upper-airway pharyngeal in Sleep Apnea (G47.30: collapse during REM), Cross-referenced with NIH MeSH (Sleep Apnea Syndromes), which Insomnia, Sleep Apnea & Sleep Health clinicians address while surveilling Nocturnal Oxygen Saturation in Sleep Apnea (G47.30: (SpO2)) (>= 94% nadir > 90% (G47.30)).
Common Symptoms & Clinical Signs
- • Presentation of Sleep Apnea (G47.30): loud habitual snoring, in Sleep Apnea (G47.30: witnessed breathing pauses,)
- • Secondary Sleep Apnea clinical sign: daytime microsleeps, cognitive in Sleep Apnea (G47.30: brain fog, or)
- • Symptom flares in Sleep Apnea correlating with Nocturnal Oxygen Saturation in Sleep Apnea (G47.30: (SpO2)) deviation outside >= 94% nadir > 90% (G47.30)
- • Functional sleep disorders impact requiring CBT-I behavioral sleep in Sleep Apnea (G47.30: efficiency tracking) evaluation (G47.30)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Sleep Apnea Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G47.30 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Insomnia, Sleep Apnea & Sleep Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Nocturnal Oxygen Saturation in Sleep Apnea (G47.30: (SpO2)) | >= 94% nadir > 90% (G47.30) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Ferritin (Restless in Sleep Apnea (G47.30: Legs)) | > 75 ng/mL (G47.30) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Apnea-Hypopnea Index (AHI) [Sleep Apnea G47.30] | < 5 events/hour (G47.30) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Sleep Apnea
Treatment selection for Sleep Apnea depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Sleep Apnea)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Exogenous melatonin on: What a 284-Participant Study Found Since 15 of the 17 studies enrolled healthy subjects or people with no relevant medical condition other than trouble sleeping, the analysis was also done including only these 15 studies. Sleep medicine reviews • 2005-02-15 • Meta-Analysis | N = 284 | 97/100 | PMID 15649737 ↗ |
| New Insights on Effect of fezolinetant on sleep disturbance and impairment during treatment of: What a 1,022-Participant Study Found Fezolinetant had a beneficial effect on four measures of sleep disturbance and impairment following treatment for VMS. Maturitas • 2024-08-15 • Phase III Randomized Trial | N = 1,022 | 96/100 | PMID 38749864 ↗ |
| New Insights on A network meta-analysis of the long- and short-term efficacy of sleep medicines: What a 25,923-Participant Study Found ORAs can be widely used in adults and the older adults, and both short-term and long-term use are effective for primary trouble sleeping. Neuroscience and biobehavioral reviews • 2021-12-15 • Meta-Analysis | N = 25,923 | 94/100 | PMID 34560134 ↗ |
| New Insights on Association between obstructive sleep apnea and male serum: What a 1,823-Participant Study Found Obstructive sleep apnea is inversely associated with male serum testosterone levels, independent of body mass index and age. Andrology • 2022-02-15 • Meta-Analysis | N = 1,823 | 94/100 | PMID 34536053 ↗ |
| New Insights on Association between obstructive sleep apnea and metabolic: What a 2,053-Participant Study Found Ten studies were included in the analysis which included 2053 patients. Clinical and investigative medicine. Medecine clinique et experimentale • 2016-10-14 • Meta-Analysis | N = 2,053 | 94/100 | PMID 27805899 ↗ |
Sleep Apnea Patient Community & “People Like Me” Threads
Filter Sleep Apnea community threads and patient logs by age, biological sex, dosage, and treatment duration.